"The U.S. Food and Drug Administration announced today that injectable drugs used in total parenteral nutrition (TPN) in critical shortage will be imported into the United States and available to patients this week.
TPN is an intravenous"...
- Patient Information:
Details with Side Effects
The basic pharmacological activity of Mellaril® (thioridazine HCl) is similar to that of other phenothiazines, but is associated with minimal extrapyramidal stimulation.
However, thioridazine has been shown to prolong the QTc interval in a dose-dependent fashion. This effect may increase the risk of serious, potentially fatal, ventricular arrhythmias, such as torsade de pointes-type arrhythmias. Due to this risk, Mellaril (thioridazine hcl) is indicated only for schizophrenic patients who have not been responsive to or cannot tolerate other antipsychotic agents (see WARNINGS and CONTRAINDICATIONS). However, the prescriber should be aware that Mellaril (thioridazine hcl) has not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown.
Last reviewed on RxList: 3/31/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Mellaril Information
Mellaril - User Reviews
Mellaril User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.